Skip to main content
SpringerLink
Log in

Issues in Anti-infective Management

  • Chapter
  • First Online:
Managing Infections in Patients With Hematological Malignancies

Part of the book series: Contemporary Hematology ((CH))

Abstract

Early antimicrobial therapy to patients with hematologic malignancies has been shown to improve their survival and outcomes. Structured properly, an institution-wide anti-infective program can improve the efficient management of infections with minimized toxicities in a cost-effective manner. Program objectives should encompass standardized approaches to antimicrobial prescribing, systems that can predict potentially dangerous therapeutic toxicities, and monitoring to assess outcome successes. This is ever more critical with the emergence of antimicrobial resistant organisms, newer expensive antimicrobial agents, and the significant drug interactions between anti-infectives and chemotherapeutic agents. Patients with HIV-associated malignancies represent a special challenge because of the complexities involved in managing two concurrent diseases and the potential for drug interactions potentiating toxicities between highly active antiretroviral therapy (HAART) and many chemotherapy agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Prentice HG (1983) Use of acyclovir for prophylaxis of herpes infections in severely immunocompromised patients. J Antimicrob Chemother 12(Suppl B):153–159

    PubMed  Google Scholar 

  2. Rolston KV (2005) Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 40(Suppl 4):S246–S252

    Article  PubMed  Google Scholar 

  3. Rolston KV, Bodey GP (2006) Comment on: empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 58(2):478–480

    Article  PubMed  CAS  Google Scholar 

  4. Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ et al (2007) Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 44(3):402–409

    Article  PubMed  Google Scholar 

  5. Feld R, Paesmans M, Freifeld AG, Klastersky J, Pizzo PA, Rolston KV et al (2002) Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clin Infect Dis 35(12):1463–1468

    Article  PubMed  Google Scholar 

  6. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751

    Article  PubMed  Google Scholar 

  7. Jun HX, Zhixiang S, Chun W, Reksodiputro AH, Ranuhardy D, Tamura K et al (2005) Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Int J Antimicrob Agents 26(Suppl 2):S128–S132

    Article  PubMed  CAS  Google Scholar 

  8. Tamura K (2005) Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. Int J Antimicrob Agents 26(Suppl 2):S123–S127

    Article  PubMed  CAS  Google Scholar 

  9. Albrecht SJ, Fishman NO, Kitchen J, Nachamkin I, Bilker WB, Hoegg C et al (2006) Reemergence of gram-negative health care-associated bloodstream infections. Arch Intern Med 166(12):1289–1294

    Article  PubMed  Google Scholar 

  10. Bratu S, Quale J, Cebular S, Heddurshetti R, Landman D (2005) Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. Eur J Clin Microbiol Infect Dis 24(3):196–201

    Article  PubMed  CAS  Google Scholar 

  11. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M et al (2005) Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 165(12):1430–1435

    Article  PubMed  CAS  Google Scholar 

  12. Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN et al (2000) Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 18(12):2476–2483

    PubMed  CAS  Google Scholar 

  13. Garey KW, Pai MP, Suda KJ, Turpin RS, Rege MD, Mingo DE et al (2007) Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 16(8):919–927

    Article  PubMed  CAS  Google Scholar 

  14. Marr KA (2004) Invasive Candida infections: the changing epidemiology. Oncology (Williston Park) 18(14 Suppl 13):9–14

    Google Scholar 

  15. Paterson DL, Lipman J (2007) Returning to the pre-antibiotic era in the critically ill: the XDR problem. Crit Care Med 35(7):1789–1791

    Article  PubMed  Google Scholar 

  16. Cosgrove SE, Patel A, Song X, Miller RE, Speck K, Banowetz A et al (2007) Impact of different methods of feedback to clinicians after postprescription antimicrobial review based on the Centers for Disease Control and Prevention’s 12 Steps to Prevent Antimicrobial Resistance Among Hospitalized Adults. Infect Control Hosp Epidemiol 28(6):641–646

    Article  PubMed  Google Scholar 

  17. Fishman N (2006) Antimicrobial stewardship. Am J Infect Control 34(5 Suppl 1):S55–S63

    Article  PubMed  Google Scholar 

  18. Forrest GN (2007) Is there a role for antimicrobial management in organ transplantation? Curr Opin Organ Transplant 12:604–609

    Article  Google Scholar 

  19. Schimpff SC, Moody M, Young VM (1970) Relationship of colonization with Pseudomonas aeruginosa to development of Pseudomonas bacteremia in cancer patients. Antimicrobial Agents Chemother (Bethesda) 10:240–244

    CAS  Google Scholar 

  20. Siddiqui AH, Harris AD, Hebden J, Wilson PD, Morris JG Jr, Roghmann MC (2002) The effect of active surveillance for vancomycin-resistant enterococci in high-risk units on vancomycin-resistant enterococci incidence hospital-wide. Am J Infect Control 30(1):40–43

    Article  PubMed  Google Scholar 

  21. Muto CA, Giannetta ET, Durbin LJ, Simonton BM, Farr BM (2002) Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 23(8):429–435

    Article  PubMed  Google Scholar 

  22. Shadel BN, Puzniak LA, Gillespie KN, Lawrence SJ, Kollef M, Mundy LM (2006) Surveillance for vancomycin-resistant enterococci: type, rates, costs, and implications. Infect Control Hosp Epidemiol 27(10):1068–1075

    Article  PubMed  Google Scholar 

  23. Procop GW, Winn W (2003) Outsourcing microbiology and offsite laboratories. Implications on patient care, cost savings, and graduate medical education. Arch Pathol Lab Med 127(5):623–624

    PubMed  Google Scholar 

  24. Binkley S, Fishman NO, LaRosa LA, Marr AM, Nachamkin I, Wordell D et al (2006) Comparison of unit-specific and hospital-wide antibiograms: potential implications for selection of empirical antimicrobial therapy. Infect Control Hosp Epidemiol 27(7):682–687

    Article  PubMed  Google Scholar 

  25. Burke JP, Pestotnik SL (1999) Antibiotic use and microbial resistance in intensive care units: impact of computer-assisted decision support. J Chemother 11(6):530–535

    PubMed  CAS  Google Scholar 

  26. Paterson DL (2006) The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43(Suppl 2):S43–S48

    Article  PubMed  Google Scholar 

  27. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP et al (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44(2):159–177

    Article  PubMed  Google Scholar 

  28. Forrest G (2006) Role of antifungal susceptibility testing in patient management. Curr Opin Infect Dis 19(6):538–543

    Article  PubMed  CAS  Google Scholar 

  29. Pfaller MA, Diekema DJ, Sheehan DJ (2006) Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 19(2):435–447

    Article  PubMed  CAS  Google Scholar 

  30. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ et al (2007) Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13, 338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods. J Clin Microbiol 45(1):70–75

    Article  PubMed  CAS  Google Scholar 

  31. Bodey GP (1981) Antibiotic prophylaxis in cancer patients: regimens of oral, nonabsorbable antibiotics for prevention of infection during induction of remission. Rev Infect Dis 3(suppl):S259–S268

    PubMed  Google Scholar 

  32. Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E et al (2007) Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 13(5):615–621

    Article  PubMed  Google Scholar 

  33. Diekema DJ, Edmond MB (2007) Look before you leap: active surveillance for multidrug-resistant organisms. Clin Infect Dis 44(8):1101–1107

    Article  PubMed  Google Scholar 

  34. Weber SG, Huang SS, Oriola S, Huskins WC, Noskin GA, Harriman K et al (2007) Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Am J Infect Control 35(2):73–85

    Article  PubMed  Google Scholar 

  35. Forrest GN (2007) PNA FISH: present and future impact on patient management. Expert Rev Mol Diagn 7(3):231–236

    Article  PubMed  CAS  Google Scholar 

  36. Peters RP, Mohammadi T, Vandenbroucke-Grauls CM, Danner SA, van Agtmael MA, Savelkoul PH (2004) Detection of bacterial DNA in blood samples from febrile patients: underestimated infection or emerging contamination? FEMS Immunol Med Microbiol 42(2):249–253

    Article  PubMed  CAS  Google Scholar 

  37. Carroll KC (2008) Rapid diagnostics for methicillin-resistant Staphylococcus aureus: current status. Mol Diagn Ther 12(1):15–24

    PubMed  CAS  Google Scholar 

  38. Stamper PD, Cai M, Lema C, Eskey K, Carroll KC (2007) Comparison of the BD GeneOhm VanR assay to culture for identification of vancomycin-resistant enterococci in rectal and stool specimens. J Clin Microbiol 45(10):3360–3365

    Article  PubMed  Google Scholar 

  39. Stamper PD, Cai M, Howard T, Speser S, Carroll KC (2007) Clinical validation of the molecular BD GeneOhm StaphSR assay for direct detection of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in positive blood cultures. J Clin Microbiol 45(7):2191–2196

    Article  PubMed  Google Scholar 

  40. Espy MJ, Uhl JR, Sloan LM, Buckwalter SP, Jones MF, Vetter EA et al (2006) Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev 19(1):165–256

    Article  PubMed  CAS  Google Scholar 

  41. Forrest GN, Mankes K, Jabra-Rizk MA, Weekes E, Johnson JK, Lincalis DP et al (2006) Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J Clin Microbiol 44(9):3381–3383

    Article  PubMed  CAS  Google Scholar 

  42. Forrest GN, Mehta S, Weekes E, Lincalis DP, Johnson JK, Venezia RA (2006) Impact of rapid in situ hybridization testing on coagulase-negative staphylococci positive blood cultures. J Antimicrob Chemother 58(1):154–158

    Article  PubMed  CAS  Google Scholar 

  43. Safdar N, Maki DG (2006) Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 43(4):474–484

    Article  PubMed  Google Scholar 

  44. Gross R, Morgan AS, Kinky DE, Weiner M, Gibson GA, Fishman NO (2001) Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 33(3):289–295

    Article  PubMed  CAS  Google Scholar 

  45. Itokazu GS, Schwartz DN, Garey KW, Rodvold KA, Danziger LH, Weinstein RA (2006) Pharmacists’ perceptions of the effectiveness of antimicrobial control programs. Am J Health Syst Pharm 63(24):2504–2508

    Article  PubMed  Google Scholar 

  46. MacDougall C, Polk RE (2005) Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 18(4):638–656

    Article  PubMed  Google Scholar 

  47. Jansen JP, Kern WV, Cornely OA, Karthaus M, Ruhnke M, Ullmann AJ et al (2006) Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 9(1):12–23

    Article  PubMed  Google Scholar 

  48. Wingard JR, Leather HL, Wood CA, Gerth WC, Lupinacci RJ, Berger ML et al (2007) Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. Am J Health Syst Pharm 64(6):637–643

    Article  PubMed  CAS  Google Scholar 

  49. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348–359

    Article  PubMed  CAS  Google Scholar 

  50. Fischer MA, Solomon DH, Teich JM, Avorn J (2003) Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients. Arch Intern Med 163(21):2585–2589

    Article  PubMed  Google Scholar 

  51. McGregor JC, Weekes E, Forrest GN, Standiford HC, Perencevich EN, Furuno JP et al (2006) Impact of a computerized clinical decision support system on reducing inappropriate antimicrobial use: a randomized controlled trial. J Am Med Inform Assoc 13(4):378–384

    Article  PubMed  Google Scholar 

  52. Mutnick AH, Ross MB (1997) Formulary management at a tertiary care teaching hospital. Pharm Pract Manag Q 17(1):63–87

    PubMed  CAS  Google Scholar 

  53. Mutnick AH, Sterba KJ, Szymusiak-Mutnick BA (1998) The integration of quality assessment and a patient-specific intervention/outcomes program. Pharm Pract Manag Q 17(4):25–36

    PubMed  CAS  Google Scholar 

  54. Knox K, Lawson W, Dean B, Holmes A (2003) Multidisciplinary antimicrobial management and the role of the infectious diseases pharmacist – a UK perspective. J Hosp Infect 53(2):85–90

    Article  PubMed  CAS  Google Scholar 

  55. Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF Jr et al (1998) A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 338(4):232–238

    Article  PubMed  CAS  Google Scholar 

  56. Pestotnik SL (2005) Expert clinical decision support systems to enhance antimicrobial stewardship programs: insights from the society of infectious diseases pharmacists. Pharmacotherapy 25(8):1116–1125

    Article  PubMed  Google Scholar 

  57. Paterson DL (2006) The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. Clin Infect Dis 42(Suppl 2):S90–S95

    Article  PubMed  Google Scholar 

  58. Schimpff SC (1986) Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 80(5C):13–20

    PubMed  CAS  Google Scholar 

  59. Wingard JR, Leather H (2005) Hepatotoxicity associated with antifungal therapy after bone marrow transplantation. Clin Infect Dis 41(3):308–310

    Article  PubMed  CAS  Google Scholar 

  60. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA et al (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103(4):1527–1533

    Article  PubMed  CAS  Google Scholar 

  61. Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, McDonald GB (2004) Cyclophosphamide metabolism is affected by azole antifungals. Blood 103(4):1557–1559

    Article  PubMed  CAS  Google Scholar 

  62. Upton A, McCune JS, Kirby KA, Leisenring W, McDonald G, Batchelder A, Marr KA (2007) Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 13(7):760–764

    Article  PubMed  CAS  Google Scholar 

  63. Bohme A, Ganser A, Hoelzer D (1995) Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 71(6):311–312

    Article  PubMed  CAS  Google Scholar 

  64. Sathiapaian RK, El-Solh H (2001) Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr Hematol Oncol 18(8):543–546

    Article  Google Scholar 

  65. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 148(10):728–736

    PubMed  Google Scholar 

  66. Sparano JA, Wiernik PH, Hu X, Sarta C, Henry DH, Ratech H (1998) Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-hodgkin’s lymphoma. Med Oncol 15(1):50–57

    Article  PubMed  CAS  Google Scholar 

  67. Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, Henry DH, Manalo J, Li T, Von Roenn JH (2004) Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin’s lymphoma: an Eastern Cooperative Oncology Group trial (E1494). J Clin Oncol 22(8):1491–1500

    Article  PubMed  CAS  Google Scholar 

  68. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B, Straus D (2001) Chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19(8):2171–2178

    PubMed  CAS  Google Scholar 

  69. Bower M, Powles T, Stebbing J, Thirlwell C (2005) Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide. J Clin Oncol 23(6):1329–1330

    Article  Google Scholar 

  70. Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G, Yarchoan R, Wilson WH (2003) Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 101(12):4653–4659

    Article  PubMed  CAS  Google Scholar 

  71. Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio BC, Palmieri F, De Luca A, Larocca LM, Ruco L, Ippolito G, Cauda R (2001) Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 15(12):1483–1491

    Article  PubMed  CAS  Google Scholar 

  72. Bower M, Gazzard B, Mandall S, Newsom-Davis T, Thirlwell C, Dhillon T, Young AM, Powles T, Gaya A, Nelson M, Stebbing J (2005) A prognostic index for systematic AIDS-related non-Hodgkin’s lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 143(4):265–273

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Oregon Health and Science University, Portland Veterans Affairs Medical Center, 3701 SW US Veterans Hospital Road P3ID, 97239, Portland, Oregon, USA

    Graeme N. Forrest M.D.

  2. Section of Infectious Diseases, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA

    Michael Kleinberg M.D., Ph.D.

Authors
  1. Graeme N. Forrest M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Kleinberg M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Kleinberg M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Maryland, S. Greene St. 22, Baltimore, 21201, U.S.A.

    Michael Kleinberg

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press

About this chapter

Cite this chapter

Forrest, G.N., Kleinberg, M. (2009). Issues in Anti-infective Management. In: Kleinberg, M. (eds) Managing Infections in Patients With Hematological Malignancies. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-415-5_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-415-5_13

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-986-4

  • Online ISBN: 978-1-59745-415-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation